Navigation Links
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Date:6/10/2013

ater than those typically used with immediate-release amantadine.

About Levodopa-Induced Dyskinesia
Levodopa (also known as L-dopa) remains the gold standard for the treatment of the debilitating motor symptoms of Parkinson's disease.  An unfortunate side effect of prolonged treatment with levodopa is the occurrence of levodopa-induced dyskinesia (LID).  LID is characterized by involuntary non-purposeful movements of the head and neck, arms, legs or trunk.  With continued levodopa treatment, and as PD progresses, LID can become severely disabling and has been associated with a decrease in the quality of life for Parkinson's patients.1  LID affects approximately 30% of patients taking levodopa2, and is particularly problematic among young-onset Parkinson's disease patients.  There are currently no medications approved for the treatment of LID.  Reducing LID and improving "on time" without troublesome dyskinesia are among the greatest patient unmet medical needs in the treatment of advanced Parkinson's disease.3

About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals is dedicated to improving the lives of those affected by central nervous system (CNS) disorders by optimizing the pharmacokinetic profiles of approved drugs to create novel treatments for use alone and as components of fixed-dose combination products.  The Company is currently advancing a pipeline of aminoadamantane-based drug candidates for the treatment of Parkinson's disease, Alzheimer's disease, and other CNS disorders.  The Phase 2/3 EASED study investigating ADS-5102 (amantadine HCl extended release) for the treatment of levodopa-induced dyskinesia in Parkinson's disease has recently been completed.  MDX-8704 (memantine HCl ER/donepezil, US) and ADS-8704 (memantine HCl ER/donepezil, ex-US) are fixed-dose combination products in late-stage investigation for the treatment of dementia associated with
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
3. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
9. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   Softworld, Inc. announced today ... practice solely focused on the specific needs of pharmaceutical, ... Softworld has already been highly successful in the clinical ... capabilities to support the quality, regulatory, and validation space. ... a combination of the current Biometric team and the ...
(Date:10/2/2014)... 2, 2014   Mast Therapeutics, Inc. (NYSE ... Edwin L. Parsley , D.O. has joined the ... President.  Dr. Parsley has been actively engaged ... in February 2014.  He has served as Mast,s interim ... Medical Officer of Aires since April 2011.  Dr. Parsley ...
(Date:10/2/2014)... BOSTON , Oct. 1, 2014   Intarcia ... two of its four phase 3 clinical trials for ... through a matchstick-sized, subcutaneous osmotic mini-pump). The first trial, ... that tested the efficacy and safety of ITCA 650 ... study demonstrated ITCA 650 to be significantly superior to ...
Breaking Medicine Technology:Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... June 20, 2011 Boston Scientific Corporation (NYSE: ... its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 ... wide range of peripheral angioplasty procedures.  The Company plans ... and other international markets. Boston Scientific ...
... Panacea Global Inc., ("the Company") (OTCQB: PANG), a biopharmaceutical ... diagnose and monitor cancer, today announced the change of the ... On June 15, 2011, the trading symbol for the Company,s ... was changed from MLXG to PANG.  This change was made ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 2Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 3Panacea Global, Inc. Files Form 8-K to Announce Name Change; Trading Symbol Changes from MLXG to PANG 2
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... New findings about brain rhythms could lead to the development ... team at Massachusetts General Hospital found that a brain rhythm ... form during sleep, where it becomes more intense at certain ... being awakened by noise or other disturbances. To test ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
... a common but painful deformity of the foot, are more likely ... found. And the more severe the bunion, the more likely ... body, leading to declines in both general and foot-specific health-related quality ... develops on the side of the big toe as it leans ...
... have discovered that a natural product isolated from a traditional ... lei gong teng, and used for hundreds of years to ... control machinery in the cell. The report, published as a ... Biology, suggests that the natural product could be a ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) ... painkillers experience cognitive problems such as confusion, disorientation and ... cancer patients from 17 health-care centers around Europe indicated ... morphine scored lower on observer-rated mental tests measuring orientation ...
... vast literature on cancer to produce a next-generation view ... cells. These hallmarks of the disease provide a ... influence biomedical researchers in their quest for new cancer ... Hanahan of cole Polytechnique Fdrale in Switzerland and Robert ...
Cached Medicine News:Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2Health News:Solving a traditional Chinese medicine mystery 2Health News:Solving a traditional Chinese medicine mystery 3Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 2Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 3Health News:In search of cancer's common ground: A next-generation view 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: